The widespread use of cardiac implantable electronic devices and wearable monitors has led to the detection of subclinical atrial fibrillation in a substantial proportion of patients. There is evidence that these asymptomatic arrhythmias are associated with increased risk of stroke. Thus, detection of subclinical atrial fibrillation may offer an opportunity to reduce stroke risk by initiating anticoagulation. However, it is unknown whether long-term anticoagulation is warranted and in what populations. This scientific statement explores the existing data on the prevalence, clinical significance, and management of subclinical atrial fibrillation and identifies current gaps in knowledge and areas of controversy and consensus.
Bibliographical noteFunding Information:
Medtronic (Fellowship Support Grant)*
© 2019 American Heart Association, Inc.
- AHA Scientific Statements
- ambulatory monitoring
- atrial fibrillation
- cardiac arrhythmia
- cardiac pacing
- cerebrovascular stroke